Anbio Biotechnology (NNNN) revenue breakdown
By region, European Union is the largest at 60% of fiscal 2025 revenue; Other Regions grew fastest, 256% a year over 2 years.
Revenue by region
Fiscal years, as Anbio Biotechnology reports them in its 10-K filings; fiscal 2025 total $9M.
| Regions | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|
| European Union | $20M | $5M | $6M | $5M | 60% |
| Asia Pacific | $3M | $73,395 | $509,168 | $2M | 18% |
| Other Regions | — | $111,050 | $472,380 | $1M | 16% |
| North America | $50,000 | $215,437 | $110,508 | $296,199 | 3% |
| South America | — | $2M | $1M | $269,538 | 3% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for NNNN.
Open NNNN in InvestinglyQuestions
Where does Anbio Biotechnology make its money?
In fiscal 2025, by region: European Union $5M, Asia Pacific $2M, Other Regions $1M, North America $296,199, South America $269,538.
From Anbio Biotechnology's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.